

Financial Results for the Year Ended March 31, 2016 <Supplement>

As of May 11, 2016

Mitsubishi Tanabe Pharma Corporation



Mitsubishi Tanabe Pharma

Table of Contents

1 Summary of Financial Results for FY2015 Ended March 31, 2016 and Forecasts for FY2016		
1. Summary of Financial Results for FY2015		
2. Summary of Forecasts for FY2016	3. Dividends 2
2 Consolidated Financial Indicators for FY2015		
1. Profit and Loss 3		
(1) Profit and Loss	(2) Cost of Sales and SG&A Expenses 3
(3) Non-operating Income and Exoense	(4) Extraordinary Income and Loss 4
(5) Taxes	 4
(6) Impacts of IFRS adoption	 5
(7) Sales of Main Products	 6
2. Financial Statement 7		
(1) Balance Sheet	 7
(2) Cash Flow Statement	 8
(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems	(4) Depreciation Costs 9
3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries 9		
3 Forecasts for FY2016 Ending March 31, 2017 (IFRS)		
(1) Consolidated Forecasts of Profit and Loss	(2) Forecasts of Cost of Sales and SG&A Expenses 10
(3) Sales Forecasts for Main Products	 11
(4) Forecast for Investment in Property, Plant and Equipment and Information Systems	 12
(5) Forecasts for Depreciation Costs	 12
4 Five-Year Financial Data		
(1) Profit and Loss	(2) Balance Sheet 13
(3) Other Financial Data	(4) Number of Employees 13
5 Quarterly Trend		
(1) Profit and Loss	 14
(2) Sales of Main Products	 15
6 State of New Product Development (as of May 11, 2016)		
1. New Drugs 16		
2. Additional Indications & Administration 17		
3. Licensing-out 18		
4. Changes Since Previous Announcement on July 31, 2015 19		
(1) New Drugs	(2) Additional Indications & Administration 19
5. Additional Information for State of New Product Development 20		
(1) New Drugs	(2) Additional Indications & Administration 20
(3) Licensing-out	 21
7 Others		
1. Subsidiaries and Affiliated Companies 22		
(1) Number of Subsidiaries and Affiliated Companies	(2) Consolidated Subsidiaries 22
(3) Affiliated Companies Accounted for by the Equity Method	 22
2. Status of Shareholders 23		
(1) Number of Outstanding Shares	 23
(2) Status of Major Shareholders	(3) Ownership and Distribution of Shares 23
(4) Trend of Dividend and Stock Price	 23
Reference		
Major Ethical Drugs / News Releases 24		

1 Summary of Financial Results for FY2015 Ended March 31, 2016 and Forecasts for FY2016

(Amounts less than ¥ 100 million are rounded.)

1. Summary of Financial Results for FY2015(Japan GAAP)

In the fiscal year ended March 31, 2016, the Company paid the upfront fees accompanying licensing-in activities and further promoted the business restructuring. On the other hand, the Company received the upfront and lump-sum payments accompanying licensing-out activities of a therapeutic agent for autoimmune diseases and a treatment agent for dyslipidemia in addition to an increase in net sales of high-priority products and vaccines, and royalty revenues of Gilenya and INVOKANA. These activities significantly contribute to the Company's business results, so that the Company records its highest in sales and major profit items.

				[Billion yen]
Net Sales	431.7	Y-on-Y	16.6	4.0 %
Domestic sales	314.8	Y-on-Y	(22.4)	(6.6 %)
Overseas sales	116.9	Y-on-Y	39.0	50.0 %
Overseas sales ratio	27.1 %	Y-on-Y	8.3 points	

In the pharmaceuticals segment, net sales were ¥431.7 billion, up 4.0%, or ¥16.6 billion, year-on-year.

Domestic sales of ethical drugs decreased by 4.9%, year-on-year, to ¥308.1 billion due to the termination of the sales alliance of the plasma fractionation products in March 2015.

Royalty income, etc. increased by 52.5%, year-on-year, to ¥92.0 billion due to the following reasons:

- Increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis
- Increase in royalty revenue from INVOKANA and the fixed dose combination with metformin (IR), for the treatment of type2 diabetes mellitus, licensed to Janssen Pharmaceuticals
- Receipt of the upfront payment accompanying the license agreement with Biogen related to MT-1303, a therapeutic agent for autoimmune diseases
- Receipt of the lump-sum payment accompanying a patent and know-how transfer agreement with Amgen and Dezima regarding TA-8995, a treatment agent for dyslipidemia (CETP inhibitor)

Operating Income	94.9	Y-on-Y	27.8	41.4 %
------------------	------	--------	------	--------

Operating income increased by 41.4%, or ¥27.8 billion, year-on-year, to ¥94.9 billion.

The cost of sales ratio improved by 4.8 percentage points, to 36.1% due to the ending of the sales alliance of the plasma fractionation products, the increase in royalty revenue and the receipt of the upfront payments. Gross profit increased by ¥30.4 billion, year-on-year, to ¥275.9 billion.

R&D expenses increased in compared with the previous fiscal year. Consequently, total SG&A expenses increased by ¥2.6 billion, year-on-year, to ¥181.0 billion.

				[Billion yen]
Ordinary Income	94.8	Y-on-Y	27.1	40.1 %

Net Income	56.4	Y-on-Y	16.9	42.9 %
------------	------	--------	------	--------

Ordinary income was up 40.1%, or ¥27.1 billion, year-on-year, to ¥94.8 billion, and net income attributable to shareholders of the Company was up 42.9%, or ¥16.9 billion, year-on-year, to ¥56.4 billion.

Non-operating income/loss was down ¥0.7 billion, year-on-year, due to the recording of foreign exchange loss.

Extraordinary income was ¥14.1 billion, due to the recording of gain on sales of investment in securities of ¥13.4 billion, in compared with ¥13.7 billion in the previous fiscal year, due to the recording of gain on sales of property, plant and equipment.

Extraordinary loss was ¥24.6 billion in fiscal year ended March 31, 2016, due to the recording of restructuring expenses of ¥16.3 billion (including the extra retirement allowances concerning subscription of early retirement program of ¥15.3 billion), and loss on impairment of fixed assets of ¥4.5 billion. On the other hand, in fiscal year ended March 31, 2015, it was ¥18.6 billion due to the recording of restructuring expenses.

2. Summary of Forecasts for FY2016(IFRS)

				[Billion yen]
Revenues	406.5	Y-on-Y	(19.3)	(4.5 %)
Core operating profit	77.0	Y-on-Y	(30.2)	(28.2 %)
Operating income	75.5	Y-on-Y	(6.6)	(8.0 %)
Profit before income	77.0	Y-on-Y	(6.5)	(7.8 %)
Net profit attributable to owners of the Company	57.0	Y-on-Y	(2.5)	(4.2 %)

The Company has voluntarily applied IFRS instead of Japan GAAP from Q1 FY2016. So, the Company shows the forecasts of FY2016 based on IFRS. Comparison with the previous year uses the reference values based on IFRS (these reference values is non-audited).

3. Dividends

	FY2016 (estimate)		FY2015	
	End of 1st Half	For the Year	End of 1st Half	For the Year
Dividends per Share (¥)	24	48	22	46
Dividends Payout Ratio	-	47.2%	-	45.7%

Dividends payout ratio in FY2015 is based on Japan GAAP and after amortization of goodwill. Dividends payout ratio in FY2016 is based on IFRS(non-depreciable of goodwill).

2 Consolidated Financial Indicators for FY2015 (JGAAP)

(Amounts less than ¥ 100 million are rounded.)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	FY2015	Y-on-Y			Comparison to previous forecasts			Notes [Y-on-Y comparison]
		FY2014	Increase (decrease)	Change %	Forecasts*	Increase (decrease)	Change %	
Net sales	431.7	415.1	16.6	4.0	429.0	2.7	0.6	See P6 "(8)Sales of Main Products" Overseas sales ratio FY2014: 18.8% FY2015: 27.1%
Domestic sales	314.8	337.2	(22.4)	(6.6)	<i>303.4</i>	11.4	3.8	
Overseas sales	116.9	77.9	39.0	50.0	<i>114.6</i>	2.3	2.0	
Cost of sales	155.8	169.6	(13.8)	(8.1)	155.0	0.8	0.5	Improved due to the ending of the sales alliance of the plasma fractionation products, increase of royalty income.
Sales cost ratio	36.1%	40.9%			36.1%			
Gross profit	275.9	245.5	30.4	12.4	274.0	1.9	0.7	
SG&A expenses	181.0	178.4	2.6	1.5	182.0	(1.0)	(0.6)	
% of net sales	41.9%	43.0%			42.4%			
Operating income	94.9	67.1	27.8	41.4	92.0	2.9	3.2	
Ordinary income	94.8	67.7	27.1	40.1	91.0	3.8	4.1	
Extraordinary income and loss	(10.5)	(5.0)	(5.5)	-	(10.5)	0.0	-	
Net income attributable to shareholders of the Company	56.4	39.5	16.9	42.9	53.0	3.4	6.5	

(2) Cost of Sales and Selling, General and Administrative Expenses

[Billion yen]

	FY2015	Y-on-Y			Comparison to previous forecasts			Notes [Y-on-Y comparison]
		FY2014	Increase (decrease)	Change %	Forecasts*	Increase (decrease)	Change %	
Cost of sales	155.8	169.6	(13.8)	(8.1)	155.0	0.8	0.5	
% of net sales	36.1%	40.9%			36.1%			
SG&A expenses	181.0	178.4	2.6	1.5	182.0	(1.0)	(0.6)	
% of net sales	41.9%	43.0%			42.4%			
R&D expenses	75.3	69.6	5.7	8.2	74.0	1.3	1.7	
% of net sales	17.4%	16.8%			17.2%			
Except R&D expenses	105.7	108.8	(3.1)	(2.8)	108.0	(2.3)	(2.1)	
Labor cost	46.6	46.8	(0.2)	(0.4)	47.0	(0.4)	(0.9)	
Amortization of goodwill	10.5	10.9	(0.4)	(3.8)	10.5	0.0	(0.0)	
Others	48.6	51.1	(2.5)	(4.8)	50.5	(1.9)	(3.7)	
Total labor cost	78.7	81.1	(2.4)	(3.0)	78.5	0.2	0.2	

*: The forecasts excluding domestic sales and overseas sales were announced on February 3, 2016 in the financial results of Q3 FY2015. The forecasts of domestic sales and overseas sales, indicated in italics, were announced on October 30, 2015 in the financial results of Q2

(3) Exchange rate

[Yen]

	FY2015 average	FY2014 average	FY2015 planned
US \$	120.16	110.62	120.00
Euro	132.53	138.43	130.00

(4) Non-operating Income and Expense

[Billion yen]

	FY2015	FY2014	Increase (decrease)	Notes
Non-operating income	4.0	3.8	0.2	
Interest income	1.8	1.6	0.2	
Dividend income	1.2	0.8	0.4	
Equity in earning of affiliates	0.0	0.0	0.0	
Foreign exchange income	-	0.4	(0.4)	
Rent income	0.2	0.2	0.0	
Others	0.7	0.8	0.0	
Non-operating expense	4.1	3.2	0.9	
Interest expense	0.2	0.2	0.0	
Loss on retirement of non-current assets	0.5	0.3	0.2	
Foreign exchange loss	0.5	-	0.5	
Loss on investment securities	0.5	0.3	0.2	
Adjustment for salaries for employees on secondment	-	0.1	(0.1)	
Donations	1.4	1.5	(0.1)	
Others	1.0	0.8	0.2	

(5) Extraordinary Income and Loss

[Billion yen]

	FY2015	FY2014	Increase (decrease)	Notes
Extraordinary income	14.1	13.7	0.5	
Gain on sales of property, plant and equipment	0.7	12.0	(11.3)	FY2015: Gain on sale of Toda dormitory and Hiranomachi building No. 1 FY2014: Gain on the sale of a vacant lot of the former Nihonbashi building
Gain on sales of investment in securities	13.4	1.1	12.4	Gain on sales of listed domestic shares, mainly
Gain on sales of shares of subsidiaries and affiliates	-	0.6	(0.6)	FY2014: Gain on the sales of shares of API Corporation and CMIC CMO ASHIKAGA
Extraordinary Loss	24.6	18.6	6.0	
Impairment loss	4.5	2.6	1.9	FY2015: Manufacturing facilities of Bipha, research building at Kashima FY2014: Toda dormitory, etc.
Restructuring expenses	16.3	12.3	4.0	FY2015: Extra retirement payments accompanied with early retirement program FY2014: Losses according to close of Kazusa office and transfer of Kashima plant (Ibaraki), etc.
Amortization of goodwill	-	3.5	(3.5)	FY2014: One-time amortization of goodwill of Bipha
Provision for reserve for HCV litigation	3.5	-	3.5	
Loss on valuation of investment in securities	0.3	0.1	0.1	
Loss on sale of investment in securities	-	0.1	(0.1)	
Others	-	0.1	(0.1)	

(5) Taxes

[Billion yen]

	FY2015	FY2014	Increase (decrease)	Notes
Income before income taxes and non-controlling interests	84.3	62.7	21.6	
Income taxes-current	30.8	29.8	1.0	
Income taxes-deferred	(0.6)	(4.4)	3.8	
Net Income	54.2	37.3	16.9	
Net income(loss) attributable to non-controlling interests	(2.3)	(2.2)	(0.1)	
Net Income attributable to shareholders of the Company	56.4	39.5	16.9	

(7) Impacts of IFRS adoption

[Billion yen]

JGAAP		IFRS*		Difference	Major causes
Items	FY2015 actual	Items	FY2015 actual, pro forma		
Sales	431.7	Revenues	425.8	(5.9)	The lump-sum payment at out-licensing of MT-1303 is recognized as deferred income: (7.2)
Cost of sales	155.8	Cost of sales	156.0	0.2	
Gross profit	275.9	Gross operation profit	269.8	(6.1)	
SG&A expenses (excluding R&D expenses)	105.7	SG&A expenses	95.9	(9.8)	The goodwill is not depreciated. (10.5)
-		Amortization of intangible assets with products	1.5	1.5	
R&D expenses	75.3	R&D expenses	64.7	(10.6)	In-licensing expenses is recognized as intangible assets. (11.4)
-	-	Others	(0.5)	(0.5)	
-	-	Core operating profit	107.2	107.2	
-	-	Non-recurring items	(25.2)	(25.2)	Reclassified from extraordinary income and loss, excluding gain on sale of investment in securities: (23.2)
Operating income	94.9	Operating income	82.1	(12.8)	
Non-operating income and loss	(0.1)	-	-	0.1	Reclassified to SG&A expense: 1.4, reclassified to financial income, financial expenses: (1.7)
-	-	Financial income, financial expenses	1.5	1.5	Reclassified from non-operating income and loss: 1.7
Extraordinary income and loss	(10.5)	-	-	10.5	Reclassified to non-recurring items: 23.2, gain on sale of investment in securities is reclassified to other comprehensive income, exempted from profit and loss: (13.4)
Income before income taxes and non-controlling interests	84.3	Profit before income taxes	83.5	(0.8)	
Net Income attributable to shareholders of the Company	56.4	Net profit attributable to owners of the Company	59.5	3.1	

*: FY2015 actual in IFRS is non-audited (pro forma).

(8) Sales of Main Products

[Billion yen]

	FY2015	Y-on-Y			Comparison to forecasts		
		FY2014	Increase (decrease)	Change %	Forecasts* ¹	Increase (decrease)	Change %
Ethical drugs	427.6	410.7	16.9	4.1	<i>413.5</i>	14.1	3.4
Ethical drugs domestic sales	308.1	323.9	(15.8)	(4.9)	<i>296.6</i>	11.5	3.9
Remicade	69.4	70.6	(1.2)	(1.7)	<i>67.7</i>	1.8	2.6
Talion	16.9	16.0	0.9	5.6	<i>16.9</i>	0.0	0.2
Ceredist	14.2	15.7	(1.5)	(9.5)	<i>13.7</i>	0.5	3.7
Tenelia(old scheme) ^{*2}	3.7	6.2	(2.6)	(41.2)	<i>3.7</i>	0.0	(0.3)
Tenelia(new scheme) ^{*2}	10.5	Undisclosed	-	-	<i>9.9</i>	0.6	6.1
Maintate	13.5	14.1	(0.7)	(4.6)	<i>13.2</i>	0.3	2.0
Simponi	12.9	10.5	2.5	23.5	<i>12.6</i>	0.3	2.7
Lexapro	9.5	8.0	1.5	19.2	<i>10.4</i>	(0.9)	(8.9)
Kremezin	9.3	10.5	(1.3)	(12.0)	<i>9.1</i>	0.2	2.3
Urso	8.2	10.0	(1.8)	(18.2)	<i>8.4</i>	(0.2)	(2.5)
Depas	7.3	8.1	(0.8)	(9.7)	<i>7.0</i>	0.3	4.3
Radicut	7.3	7.4	(0.1)	(1.5)	<i>6.2</i>	1.1	17.0
Anplag	6.4	8.3	(1.9)	(22.5)	<i>6.4</i>	0.1	1.1
BIKEN products [vaccine]	39.1	30.3	8.8	29.1	<i>32.6</i>	6.4	19.7
Influenza	13.8	7.4	6.4	86.5	<i>11.2</i>	2.6	22.8
Tetrabik	9.5	7.5	2.0	26.5	<i>7.4</i>	2.1	28.5
Varicella vaccine	6.4	7.2	(0.8)	(11.2)	<i>Undisclosed</i>	-	-
Mearubik	5.0	4.0	1.0	26.0	<i>Undisclosed</i>	-	-
Tanabe Seiyaku Hanbai products * ³	13.8	13.6	0.2	1.6	<i>14.0</i>	(0.2)	(1.4)
Ethical drugs overseas sales	25.2	23.0	2.2	9.6	<i>25.2</i>	0.0	0.0
Herbesser	6.5	6.5	0.0	0.1	<i>6.8</i>	(0.3)	(4.5)
Argatroban (Novastan)	2.7	2.1	0.6	26.5	<i>2.8</i>	(0.1)	(3.7)
Tanatril	1.6	1.8	(0.2)	(12.9)	<i>1.7</i>	(0.1)	(6.8)
Contracted manufacturing products * ⁴	2.2	3.4	(1.2)	(35.2)	<i>2.1</i>	0.1	6.2
Royalty income, etc.	92.0	60.4	31.7	52.5	<i>89.6</i>	2.4	2.7
Royalty from Gilenya	51.7	43.9	7.8	17.7	<i>Undisclosed</i>	-	-
Royalty from INVOKANA	20.6	9.8	10.9	111.2	<i>Undisclosed</i>	-	-
OTC products	3.8	4.0	(0.2)	(5.8)	<i>4.1</i>	(0.3)	(8.3)
Total sales	431.7	415.1	16.6	4.0	<i>429.0</i>	2.7	0.6

*1: The forecast of total pharmaceuticals was announced on February 3, 2016 in the financial results of Q3 FY2015. The other forecasts, indicated in italics, were announced on October 30, 2015 in the financial results of Q2 FY2015.

*2: The sales scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015. Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company discloses total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*3: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from the Company.

*4: Active pharmaceutical ingredients and others ordered by other companies.

2. Financial Statement

(1) Balance Sheet

[Billion Yen]

	End of FY2015	Composition %	End of FY2014	Increase (decrease)	Notes
Total assets	930.2	100.0	929.3	0.9	
Current assets	657.3	70.7	603.6	53.6	
Cash and deposits	142.7	15.3	50.2	92.5	See Page8, (2) Cash Flow Statement
Marketable securities	96.5	10.4	118.8	(22.3)	Decrease in negotiable deposit and corporate bonds, etc.
Notes and accounts receivable - trade ^{*1}	121.3	13.0	130.3	(9.0)	
Inventories	75.6	8.1	85.1	(9.5)	
Deposits	193.1	20.8	192.8	0.4	
Deferred income taxes	7.3	0.8	8.3	(1.0)	
Other	20.7	2.2	18.1	2.6	
Fixed assets	273.0	29.3	325.7	(52.7)	
Property, plant and equipment	88.3	9.5	92.5	(4.2)	Investment in plant and equipment, 11.2; depreciation, (7.3); disposal, sale, impairment and others, (6.7)
Intangible fixed assets	102.6	11.0	116.9	(14.3)	Investment in information system, 0.9; depreciation, (1.4); amortization of goodwill of the merger, (10.0)
Investment in securities	49.8	5.4	76.3	(26.5)	Decrease due to sale of listed domestic shares
Deferred income taxes	6.1	0.7	0.8	5.3	
Net defined benefit asset	8.2	0.9	15.7	(7.6)	
Other	18.1	1.9	23.4	(5.3)	
Total liabilities	113.5	12.2	128.9	(15.3)	
Current liabilities	91.3	9.8	105.4	(14.1)	
Notes and accounts payable - trade ^{*2}	32.7	3.5	34.6	(1.9)	
Current maturities of long-term debt	0.1	0.0	0.1	0.0	
Accounts payable, other	19.8	2.1	25.4	(5.6)	
Income taxes payable	17.5	1.9	19.8	(2.3)	
Reserve for employees' bonuses	10.7	1.1	10.0	0.7	
Other	10.5	1.1	15.5	(5.0)	
Long-term liabilities	22.2	2.4	23.5	(1.2)	
Long-term debts	0.7	0.1	0.9	(0.2)	
Deferred tax liabilities	7.5	0.8	9.8	(2.2)	
Reserve for health management allowances for HIV compensation	1.6	0.2	1.7	(0.1)	
Reserve for health management allowances for SMON compensation	2.5	0.3	2.7	(0.2)	
Reserve for HCV litigation	5.0	0.5	2.0	3.0	Provision, 3.5
Net defined benefit liability	1.4	0.1	2.5	(1.1)	
Other	3.5	0.4	3.9	(0.4)	
Net assets	816.7	87.8	800.4	16.3	
Shareholders' equity	807.8	86.8	776.0	31.7	
Common stock	50.0	5.4	50.0	-	
Capital surplus	451.2	48.5	451.2	-	
Retained earnings	307.1	33.0	275.3	31.8	Net income attributable to shareholders of the Company, 56.4; payment for dividends, (24.7)
Treasury stock, at cost	(0.5)	(0.1)	(0.5)	0.0	
Accumulated other comprehensive loss	(1.8)	(0.2)	13.0	(14.8)	
Unrealized holding (losses) gains on securities	11.9	1.3	14.9	(3.1)	
Deferred (losses) gains on hedges	0.0	0.0	0.1	(0.1)	
Translation adjustments	(3.8)	(0.4)	0.1	(3.9)	
Remeasurements of defined benefit plans	(9.9)	(1.1)	(2.2)	(7.7)	
Non-controlling interests	10.8	1.2	11.5	(0.7)	

*1: Notes and accounts receivable - trade = Bills + Accounts receivable

*2: Notes and account payable - trade=Bills(except non-operating bills)+Accounts payable

(2) Cash Flow Statement

[Billion yen]

	FY2015	FY2014	Increase (decrease)
Cash and cash equivalents at beginning of year	73.3	85.0	(11.6)
Cash flows from operating activities	65.2	68.2	(3.0)
Income before income taxes and non-controlling interests	84.3	62.7	21.6
Depreciation and amortization	8.8	9.0	(0.2)
Loss on impairment of fixed assets	4.5	2.6	1.9
Amortization of goodwill	10.5	14.4	(3.9)
Increase (decrease) in net defined benefit liabilities	(0.8)	(0.5)	(0.3)
Decrease (increase) in net defined benefit asset	(4.6)	(3.9)	(0.7)
Increase (decrease) in reserve for HCV litigation	3.0	(0.6)	3.6
Interest and dividend income	(3.0)	(2.4)	(0.6)
Loss (gain) on sale of property, plant and equipment	(0.2)	(11.8)	11.6
Restructuring expenses	16.3	12.3	4.0
Loss (gain) on sales of shares of subsidiaries and affiliates	-	(0.6)	0.6
Loss (gain) on sale of investment in securities	(13.4)	(1.0)	(12.4)
Decrease(increase) in notes and accounts receivable-trade	8.7	(6.7)	15.4
Decrease (increase) in inventories	6.3	7.8	(1.5)
Increase(decrease) in notes and accounts payable - trade	(1.7)	0.5	(2.2)
Increase(decrease) in accounts payable, other	(4.4)	5.9	(10.4)
Interest and dividend received	3.0	2.4	0.6
Extra retirement payments	(15.3)	-	(15.3)
Income taxes paid	(33.7)	(20.0)	(13.8)
Other, net	(3.0)	(2.0)	(1.1)
Cash flows from investing activities	(26.6)	(59.8)	33.3
Purchase/sales etc. of marketable securities	41.3	(26.4)	67.7
Increase/decrease in time deposits	(93.6)	(20.2)	(73.4)
Increase in deposits	(0.4)	(20.6)	20.2
Purchase/sales of property, plant and equipment	(9.1)	(1.3)	(7.8)
Purchase of intangible fixed assets	(1.2)	(1.5)	0.4
Purchase/sales of investment in securities	30.0	1.1	29.0
Proceeds from sales of shares of subsidiaries and associates	-	7.6	(7.6)
Proceeds from company split	3.3	-	3.3
Proceeds from business transfer	3.0	-	3.0
Proceeds from sales of shares of subsidiaries accompanying changes in the scope of consolidation	-	1.5	(1.5)
Other, net	0.0	0.0	(0.1)
Cash flows from financing activities	(22.2)	(21.9)	(0.4)
Increase (decrease) in short-term debt, net	-	(1.2)	1.2
Proceeds from share issuance to non-controlling shareholders	2.8	2.6	0.2
Cash dividends paid	(24.7)	(22.4)	(2.2)
Cash dividends paid to non-controlling shareholders	(0.1)	(0.6)	0.5
Other, net	(0.2)	(0.2)	0.0
Effect of exchange rate change on cash and cash equivalents	(0.8)	1.9	(2.7)
Net increase (decrease) in cash and cash equivalents	15.6	(11.6)	27.2
Cash and cash equivalents at end of the year	88.9	73.3	15.6

The Reconciliation of Cash and Cash Equivalents in the Consolidated Balance Sheets and Cash and Cash Equivalents in the Consolidated Statements of Cash Flows at the End of the Period [Billion yen]

	FY2015	FY2014
Cash and time deposits	142.7	50.2
Time deposits maturing after three months	(118.0)	(25.6)
Short-term investments in marketable securities maturing within three months of acquisition	43.0	28.0
Cash equivalents included in short-term loans receivable*	1.2	0.7
Cash equivalents included in deposits	20.0	20.0
Cash and cash equivalents in the consolidated statements of cash flows	88.9	73.3

*: Short-term loans are included in "Others, Current Assets" on page 7.

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

	FY2015	FY2014	Increase (decrease)
Investment in property, plant and equipment / occurring basis	11.2	15.7	(4.5)
Investment in information systems/ occurring basis	0.9	1.6	(0.6)

[Billion yen]

Major investment in property, plant and equipment in FY2015		Major investment in development of information systems in FY2015	
Mitsubishi Tanabe Pharma	3.7	Mitsubishi Tanabe Pharma	0.7
Mitsubishi Tanabe Pharma Factory	5.1		
[Construction of new pharmaceutical production building at Yoshitomi plant]	[2.1]		
[Restructuring of injection products facilities at Onoda plant]	[1.5]		

(4) Depreciation Costs

[Billion yen]

	FY2015	FY2014	Increase (decrease)
Property, plant and equipment	7.3	7.5	(0.2)
Intangible fixed assets	1.6	1.6	0.0

3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries

[Billion yen]

	Companies	Mitsubishi Tanabe Pharma Factory Ltd.	Tanabe Seiyaku Hanbai Co., Ltd.	Mitsubishi Tanabe Pharma Korea Co., Ltd.	Medicago, Inc.	Tianjin Tanabe Seiyaku Co., Ltd.	P.T. Tanabe Indonesia
Net sales	FY2015	29.0	13.8	4.6	0.3	5.3	1.7
	FY2014	39.4	13.6	4.4	1.1	4.5	2.3
Operating income	FY2015	2.6	(0.5)	0.3	(6.0)	0.3	(0.1)
	FY2014	3.6	(0.1)	0.2	(5.1)	0.5	0.1
Ordinary income	FY2015	2.6	(0.5)	0.3	(6.3)	0.1	(0.1)
	FY2014	3.6	(0.1)	0.3	(5.2)	0.5	0.1
Net income attributable to shareholders of the Company	FY2015	1.0	(0.7)	0.2	(6.3)	0.0	(0.1)
	FY2014	0.7	(0.1)	0.2	(5.3)	0.3	0.0
R&D expenses	1H FY2015	0.8	-	-	6.3	0.2	0.0
	FY2014	1.3	-	-	6.2	0.2	0.0
Depreciation of property, plant and equipment	FY2015	1.8	0.0	0.1	0.6	0.2	0.1
	FY2014	2.2	0.0	0.1	0.4	0.1	0.1
Total assets	End of FY2015	48.6	6.6	3.7	33.2	5.4	2.9
	End of FY2014	48.2	6.0	3.7	35.6	6.1	3.1
Net assets	End of FY2015	37.6	0.2	2.8	22.6	3.3	1.5
	End of FY2014	36.9	0.3	3.0	24.2	3.9	1.7
Number of employees	End of FY2015	839	156	128	291	562	404
	End of FY2014	1,087	168	121	263	537	441

Note: Prior to elimination of internal transaction

3 Forecasts for FY2016 Ending march 31, 2017 (IFRS)

(Amounts less than ¥ 100 million are rounded)

(1) Consolidate Forecasts of Profit and Loss

[Billion yen]

	1H FY2016 forecasts	FY2016 forecasts	FY2015 actual (pro forma)*	Increase (decrease)	Change(%)	Notes [Y-on-Y comparison]
Revenues	193.0	406.5	425.8	(19.3)	(4.5)	See P11"(3) Sales Forecasts for Main Products". Overseas sales ratio FY2015: 25.9% FY2016 estimation : 24.3%
Domestic sales	144.9	307.8	315.4	(7.6)	(2.4)	
Overseas sales	48.1	98.7	110.4	(11.7)	(10.6)	
Cost of sales	72.5	159.0	156.0	3.0	1.9	Sales cost ratio is worsened by NHI drug price revision, etc.
Sales cost ratio	37.6%	39.1%	36.6%			
Gross profit	120.5	247.5	269.8	(22.3)	(8.3)	
SG & A expenses	48.0	98.5	95.9	2.6	2.7	
Amortization of intangible assets with products	0.7	1.5	1.5	-	-	
R&D expenses	33.5	70.0	64.7	5.3	8.2	
Other profit and loss	(0.3)	(0.5)	(0.5)	-	-	
Core operating profit	38.0	77.0	107.2	(30.2)	(28.2)	
Non-recurring items	-	(1.5)	(25.2)	23.7	-	
Operating income	38.0	75.5	82.1	(6.6)	(8.0)	
Financial income, financial expense	0.5	1.5	1.5	-	-	
Profit before income taxes	38.5	77.0	83.5	(6.5)	(7.8)	
Net profit attributable to owners of the Company	28.5	57.0	59.5	(2.5)	(4.2)	

Total labor costs	37.5	75.0	80.5	(5.5)	(6.8)	Decrease due to the early retirement program; increase due to US business development
-------------------	------	------	------	-------	-------	---

*: FY2015 actual is non-audited (pro forma).

(3) Exchange rate

[Yen]

	FY2016 planned	FY2015 average
US \$	110.00	120.16
Euro	120.00	132.53

(3) Sales Forecasts for Main Products

[Billion yen]

	1H FY2016 forecasts	FY2016 forecasts	FY2015 actual, pro forma	Increase (decrease)	Change %
Ethical drugs	190.6	402.2	421.6	(19.4)	(4.6)
Ethical drugs domestic sales	141.2	300.9	308.1	(7.2)	(2.3)
Remicade	31.7	62.5	69.4	(6.9)	(9.9)
Simponi	11.3	23.4	12.9	10.5	81.0
Tenelia (old scheme) ^{*1}	-	-	3.7	(3.7)	(100.0)
Tenelia (new scheme) ^{*1}	8.3	17.5	10.5	7.0	66.7
Talion	6.7	17.3	16.9	0.4	2.7
Lexapro	5.7	12.6	9.5	3.1	32.9
Ceredist	6.3	12.3	14.2	(1.9)	(13.6)
Maintate	5.4	10.7	13.5	(2.8)	(20.5)
Kremezin	3.8	7.3	9.3	(1.9)	(20.7)
Urso	3.5	6.8	8.2	(1.4)	(17.5)
Depas	3.2	6.2	7.3	(1.0)	(14.2)
Radicut	2.9	5.8	7.3	(1.5)	(20.5)
BIKEN products [vaccine]	13.8	33.6	39.1	(5.4)	(13.9)
Influenza	2.0	11.1	13.8	(2.6)	(19.2)
Tetrabik	4.0	8.6	9.5	(0.9)	(9.9)
Varicella vaccine	2.9	5.5	6.4	(0.8)	(12.8)
Tanabe Seiyaku Hanbai products ^{*2}	6.9	14.3	13.8	0.5	3.5
Ethical drugs overseas sales	10.2	21.8	25.2	(3.4)	(13.7)
Herbesser	2.9	6.1	6.5	(0.4)	(5.8)
Argatroban (Novastan)	0.9	1.8	2.7	(0.9)	(31.6)
Tanatril	0.9	1.6	1.6	0.0	2.8
Simponi	0.7	1.5	1.3	0.2	16.8
Contracted manufacturing products ^{*3}	0.9	1.6	2.2	(0.6)	(29.1)
Royalty income, etc.	38.3	78.0	86.1	(8.2)	(9.5)
Royalty from Gilenya	Undisclosed	Undisclosed	51.7	-	-
Royalty from INVOKANA	Undisclosed	Undisclosed	20.6	-	-
OTC products	2.3	4.1	3.8	0.3	8.9
Total revenues	193.0	406.5	425.8	(19.3)	(4.5)

*1: The sales scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015. Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company discloses total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from the Company.

*3: Active pharmaceutical ingredients and others ordered by outside companies.

(4) Forecasts of Investment for Property, Plant and Equipment and Information Systems

[Billion yen]

	1H FY2016 forecasts	FY2016 forecasts	FY2015 actual	Increase (decrease)	Change %
Investment in property, plant and equipment/occurring basis	8.3	14.3	11.2	3.1	2.7
Investment for information systems/occurring basis	1.2	1.7	0.9	0.8	8.1

[Billion yen]

Major investment in property, plant and equipment in FY2016		Major investment for information systems in FY2016	
Production facilities	10.6	R&D related systems	0.5
[Construction of new manufacturing facility at Yoshitomi plant]	[6.2]	Production related system	0.3
Facilities & equipment for R&D	3.2	Others	0.9
Others	0.5		

(5) Forecasts for Depreciation Costs

[Billion yen]

	1H FY2016 forecasts	FY2016 forecasts	FY2015 actual	Increase (decrease)	Change %
Property, plant and equipment, depreciation cost	3.6	7.5	7.3	0.2	3.2
Intangible fixed assets, depreciation cost	0.8	1.6	1.6	0.0	1.9
Intangible assets with products, amortization cost	0.7	1.5	1.5	-	-

4 Five-Year Financial Data

(Amounts less than ¥100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2011	FY2012	FY2013	FY2014	FY2015
Net sales	407.2	419.2	412.7	415.1	431.7
Cost of sales	152.3	166.4	169.4	169.6	155.8
Gross operation profit	254.9	252.8	243.3	245.5	275.9
SG&A expenses	185.8	183.8	184.2	178.4	181.0
R&D expenses	70.2	66.5	70.4	69.6	75.3
Operating income	69.0	69.0	59.1	67.1	94.9
Ordinary income	68.8	69.4	61.9	67.7	94.8
Extraordinary income	1.2	4.2	15.3	13.7	14.1
Extraordinary loss	6.1	5.9	4.8	18.6	24.6
Net income attributable to shareholders of the Company	39.0	41.9	45.4	39.5	56.4

(2) Balance Sheet

[Billion yen]

	End of FY2011	End of FY2012	End of FY2013	End of FY2014	End of FY2015
Total assets	819.9	866.8	886.5	929.3	930.2
Current assets	419.7	476.7	540.5	603.6	657.3
Fixed assets	400.3	390.1	346.0	325.7	273.0
Total liabilities	98.4	113.9	108.6	128.9	113.5
Current liabilities	69.6	86.1	81.8	105.4	91.3
Fixed liabilities	28.9	27.7	26.8	23.5	22.2
Net assets	721.5	752.9	777.8	800.4	816.7

(3) Other Financial Data

[Billion yen]

	FY2011	FY2012	FY2013	FY2014	FY2015
Cash flows from operating activities	37.2	60.6	69.9	68.2	65.2
Cash flows from investing activities	(63.2)	(35.0)	(24.3)	(59.8)	(26.6)
Cash flows from financing activities	(17.2)	(23.7)	(21.1)	(21.9)	(22.2)
Investments in property, plant and equipment	7.1	9.2	12.6	15.7	11.2
Investments for development of information systems	1.2	2.2	2.1	1.6	0.9
Depreciation costs	12.5	8.4	9.2	9.0	8.8
Equity ratio (%)	87.3	86.3	86.4	84.9	86.6
ROE (%)	5.5	5.7	6.0	5.1	7.1
Net income per share (¥)	69.54	74.67	80.92	70.41	100.60
Net assets per share (¥)	1,275.85	1,333.22	1,365.52	1,406.41	1,436.63

(4) Number of Employees

	End of FY2011	End of FY2012	End of FY2013	End of FY2014	End of FY2015	Forecast for end of FY2016
Consolidated	9,180	8,835	9,065	8,457	8,125	7,607
Non-consolidated	4,826	4,850	4,867	4,844	4,780	4,333

5 Quarterly Trend (Japan GAAP basis)

(Amounts less than ¥ 100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2014					FY2015				
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full year Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full year forecasts
Net sales	94.6 22.8%	104.3 25.1%	120.9 29.1%	95.3 23.0%	415.1 100.0%	98.5 22.8%	103.2 23.9%	139.2 32.2%	90.8 21.0%	431.7 100.0%
Domestic	79.8 23.7%	85.3 25.3%	98.6 29.2%	73.6 21.8%	337.2 100.0%	76.3 24.2%	74.6 23.7%	95.0 30.2%	68.9 21.9%	314.8 100.0%
Overseas	14.8 19.0%	19.1 24.5%	22.3 28.7%	21.7 27.9%	77.9 100.0%	22.2 19.0%	28.6 24.5%	44.2 37.8%	21.9 18.7%	116.9 100.0%
Cost of sales	39.2	39.0	49.8	41.6	169.6	35.5	37.6	47.7	35.0	155.8
Sales cost ratio	41.4%	37.4%	41.2%	43.6%	40.9%	36.1%	36.5%	34.2%	38.5%	36.1%
Gross profit	55.4 22.6%	65.3 26.6%	71.0 28.9%	53.8 21.9%	245.5 100.0%	63.0 22.8%	65.6 23.8%	91.5 33.2%	55.8 20.2%	275.9 100.0%
SG&A expenses	41.7 23.4%	44.1 24.7%	42.4 23.8%	50.2 28.2%	178.4 100.0%	40.2 22.2%	44.8 24.8%	43.1 23.8%	52.8 29.2%	181.0 100.0%
R&D expenses	16.3 23.5%	15.6 22.4%	16.2 23.2%	21.5 30.9%	69.6 100.0%	15.5 20.5%	17.8 23.6%	17.0 22.6%	25.0 33.2%	75.3 100.0%
Non-R&D expenses	25.3 23.3%	28.5 26.2%	26.3 24.1%	28.7 26.4%	108.8 100.0%	24.8 23.4%	27.0 25.6%	26.1 24.7%	27.8 26.3%	105.7 100.0%
Labor costs	11.1 23.8%	11.9 25.5%	11.8 25.2%	12.0 25.6%	46.8 100.0%	11.2 24.0%	11.8 25.4%	11.8 25.2%	11.8 25.3%	46.6 100.0%
Amortization of goodwill	2.7 24.7%	2.7 24.7%	2.7 24.7%	2.8 25.8%	10.9 100.0%	2.6 25.1%	2.6 25.0%	2.6 25.0%	2.6 24.9%	10.5 100.0%
Others	11.5 22.6%	13.9 27.1%	11.8 23.1%	13.9 27.2%	51.1 100.0%	10.9 22.5%	12.6 25.9%	11.8 24.2%	13.4 27.5%	48.6 100.0%
Operating income	13.7 20.4%	21.3 31.7%	28.6 42.7%	3.5 5.3%	67.1 100.0%	22.7 24.0%	20.8 21.9%	48.4 51.0%	3.0 3.2%	94.9 100.0%
Ordinary income	14.6 21.5%	20.9 30.9%	28.6 42.3%	3.6 5.3%	67.7 100.0%	22.6 23.9%	20.7 21.8%	48.7 51.4%	2.8 2.9%	94.8 100.0%
Net income attributable to shareholders of the Company	9.6 24.3%	22.9 58.1%	15.8 39.9%	(8.8) (22.3%)	39.5 100.0%	14.9 26.4%	14.3 25.3%	30.9 54.8%	(3.7) (6.5%)	56.4 100.0%

The each figure (excluding "cost of sales") in the lower displays the progress rate.

(2) Sales of Main Products

[Billion yen]

	FY2014					FY2015				
	Q1	Q2	Q3	Q4	Full year	Q1	Q2	Q3	Q4	Full year
	Apr. to Jun.	Jul. to Sep.	Oct. to Dec.	Jan. to Mar.	actual	Apr. to Jun.	Jul. to Sep.	Oct. to Dec.	Jan. to Mar.	actual
Ethical drugs	93.2	103.3	119.8	94.4	410.7	97.2	102.2	138.1	90.0	427.6
	22.7%	25.1%	29.2%	23.0%	100.0%	22.7%	23.9%	32.3%	21.0%	100.0%
Ethical drugs domestic sales	77.5	77.7	96.8	71.9	323.9	74.3	73.1	93.3	67.4	308.1
	23.9%	24.0%	29.9%	22.2%	100.0%	24.1%	23.7%	30.3%	21.9%	100.0%
Remicade	17.3	17.9	19.3	16.1	70.6	16.9	17.6	19.5	15.4	69.4
	24.6%	25.3%	27.3%	22.8%	100.0%	24.3%	25.4%	28.1%	22.2%	100.0%
Talion	3.3	2.8	4.3	5.7	16.0	3.6	2.9	4.8	5.7	16.9
	20.3%	17.7%	26.6%	35.4%	100.0%	21.1%	17.0%	28.1%	33.8%	100.0%
Ceredist	4.1	3.8	4.4	3.4	15.7	3.9	3.5	4.1	2.7	14.2
	26.4%	24.0%	27.9%	21.7%	100.0%	27.4%	24.6%	28.7%	19.3%	100.0%
Tenelia (old scheme) ^{*1}	1.1	1.6	1.9	1.7	6.2	2.0	1.7	(0.1)	0.0	3.7
	17.9%	24.9%	30.6%	26.5%	100.0%	55.6%	46.5%	(2.1%)	0.0%	100.0%
Tenelia (new scheme) ^{*1}	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	4.3	3.2	10.5
	-	-	-	-	-	-	-	41.3%	30.7%	100.0%
Maintate	3.8	3.4	3.8	3.2	14.1	3.7	3.2	3.8	2.8	13.5
	26.7%	23.9%	26.8%	22.6%	100.0%	27.4%	24.0%	27.9%	20.8%	100.0%
Simponi	2.5	2.6	2.9	2.5	10.5	3.0	3.2	3.6	3.1	12.9
	23.5%	24.6%	27.9%	23.9%	100.0%	23.4%	24.4%	28.0%	24.2%	100.0%
Lexapro	1.7	1.7	2.7	1.8	8.0	2.1	2.2	3.0	2.1	9.5
	21.1%	21.7%	34.3%	22.9%	100.0%	22.5%	23.6%	31.9%	22.0%	100.0%
Kremezin	2.8	2.6	2.8	2.3	10.5	2.5	2.3	2.6	1.9	9.3
	26.6%	24.9%	26.8%	21.8%	100.0%	27.2%	24.8%	27.7%	20.3%	100.0%
Urso	2.7	2.4	2.7	2.2	10.0	2.4	2.0	2.2	1.6	8.2
	26.7%	24.2%	27.0%	22.1%	100.0%	29.0%	24.8%	27.1%	19.0%	100.0%
Depas	2.1	2.0	2.2	1.8	8.1	1.9	1.8	2.0	1.5	7.3
	25.9%	24.9%	27.1%	22.2%	100.0%	26.7%	24.3%	27.7%	21.2%	100.0%
Radicut	2.0	1.8	2.1	1.5	7.4	1.7	1.8	2.2	1.7	7.3
	26.7%	24.7%	28.3%	20.3%	100.0%	22.8%	24.3%	30.2%	22.7%	100.0%
Anplag	2.4	2.0	2.2	1.7	8.3	1.9	1.6	1.8	1.2	6.4
	28.7%	23.9%	27.0%	20.5%	100.0%	29.8%	24.2%	27.7%	18.3%	100.0%
BIKEN products [vaccines]	4.9	6.2	14.8	4.4	30.3	6.3	8.2	17.0	7.6	39.1
	16.2%	20.4%	48.8%	14.5%	100.0%	16.1%	21.0%	43.6%	19.3%	100.0%
Influenza	(0.1)	0.9	7.3	(0.8)	7.4	0.0	2.8	9.3	1.7	13.8
	(0.7%)	12.7%	99.3%	(11.3%)	100.0%	(0.2%)	20.4%	67.5%	12.4%	100.0%
Tetrabik	1.8	1.8	2.1	1.8	7.5	1.9	1.7	3.6	2.3	9.5
	23.6%	23.7%	28.2%	24.4%	100.0%	20.3%	18.1%	37.7%	23.9%	100.0%
Varicella vaccine	0.6	1.3	3.5	1.7	7.2	1.8	1.5	1.6	1.4	6.4
	8.7%	18.2%	48.8%	24.3%	100.0%	28.1%	24.3%	25.8%	21.8%	100.0%
Mearubik	1.3	0.9	0.9	0.9	4.0	1.4	1.1	1.3	1.2	5.0
	31.7%	23.4%	21.5%	23.4%	100.0%	29.0%	21.4%	25.7%	23.8%	100.0%
Tanabe Seiyaku Hanbai products ^{*2}	3.4	3.1	3.9	3.3	13.6	3.4	3.2	4.0	3.2	13.8
	24.8%	22.5%	28.6%	24.0%	100.0%	24.7%	23.2%	28.7%	23.4%	100.0%
Ethical drugs overseas sales	5.3	6.0	5.5	6.2	23.0	6.2	8.1	5.5	5.4	25.2
	23.0%	26.3%	23.7%	27.1%	100.0%	24.5%	32.0%	21.9%	21.6%	100.0%
Herbesser	1.6	1.9	1.4	1.6	6.5	1.5	1.6	1.6	1.8	6.5
	24.4%	29.1%	22.3%	24.2%	100.0%	23.2%	24.7%	24.5%	27.6%	100.0%
Argatroban (Novastan)	0.7	0.6	0.5	0.4	2.1	0.5	1.1	0.6	0.5	2.7
	32.5%	26.5%	22.9%	18.1%	100.0%	17.6%	40.8%	22.1%	19.5%	100.0%
Tanatril	0.5	0.6	0.4	0.4	1.8	0.5	0.4	0.4	0.4	1.6
	24.7%	31.4%	21.8%	22.1%	100.0%	28.5%	24.0%	25.4%	22.0%	100.0%
Contracted manufacturing products ^{*3}	0.9	1.2	0.5	0.8	3.4	0.6	0.5	0.4	0.7	2.2
	27.0%	34.6%	15.1%	23.2%	100.0%	25.9%	22.2%	20.1%	31.7%	100.0%
Royalty income, etc.	9.5	18.4	17.0	15.5	60.4	16.2	20.6	38.9	16.4	92.0
	15.7%	30.4%	28.2%	25.7%	100.0%	17.6%	22.4%	42.2%	17.8%	100.0%
Royalty from Gilenya	7.7	11.1	13.7	11.4	43.9	11.2	14.6	14.0	11.9	51.7
	17.6%	25.3%	31.1%	26.0%	100.0%	21.7%	28.2%	27.1%	22.9%	100.0%
Royalty from INVOKANA	Undisclosed	Undisclosed	Undisclosed	3.6	9.8	4.6	5.4	6.8	4.0	20.6
	-	-	-	37.3%	100.0%	22.1%	26.0%	32.8%	19.2%	100.0%
OTC products	1.2	1.0	1.0	0.8	4.0	1.2	0.9	1.0	0.7	3.8
	30.4%	24.2%	24.9%	20.4%	100.0%	31.0%	24.8%	25.3%	18.9%	100.0%
Total sales	94.6	104.3	120.9	95.3	415.1	98.5	103.2	139.2	90.8	431.7
	22.8%	25.1%	29.1%	23.0%	100.0%	22.8%	23.9%	32.2%	21.0%	100.0%

The each figure in the lower displays the progress rate.

*1: The scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015.

Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company discloses total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from the Company.

*3: Active pharmaceutical ingredients and others ordered by outside companies.

6 State of New Product Development (as of May 11, 2016)

1. New Drugs

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
TA-7284 (canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Taiwan	Filed (Mar., 2015)	In-house
MP-513 (teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Indonesia	Filed (Apr., 2015)	In-house
		Europe	Phase 2	
		US	Phase 1	
TAU-284 (bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis, Pediatric atopic dermatitis)	China	Filed (Mar., 2016)	Japan: Ube Industries
MT-2412 (teneligliptin, canagliflozin)	Fixed-dose combination of DPP-4 inhibitor and SGLT2 inhibitor (Type 2 diabetes mellitus)	Japan	Phase 3	In-house
MP-214 (cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Japan,Asia	Phase 2b/3	Hungary: Gedeon Richter
MT-4666 (encenicline)	α 7nACh receptor agonist (Dementia of Alzheimer's type)	Japan	Phase 2	US: FORUM Pharmaceuticals
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe	Phase 2	In-house
		Japan	Phase 2	
		US	Phase 1	
MT-1303 (amiselimod)	S1P receptor functional antagonist (Multiple sclerosis)	Europe	Phase 2	In-house
	(Psoriasis)	Europe	Phase 2	
	(Crohn's disease)	Japan,Europe	Phase 2	
	(Inflammatory diseases, autoimmune diseases)	Japan,Europe, US	Phase 1	
MT-2301	Haemophilus influenza type b (Hib) vaccine (Prophylaxis of pediatric Hib infection)	Japan	Phase 2	US: Nuron Biotech
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada	Phase 2	In-house
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of seasonal influenza)	US, Canada	Phase 2	In-house
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Canada	Phase 1	In-house
GB-1057 (recombinant human serum albumin)	Blood and blood forming organs	US	Phase 1	In-house
MP-124	Nervous system	US	Phase 1	In-house
MP-157	Cardiovascular system	Europe	Phase 1	In-house
MT-0814	Ophthalmologicals	Japan	Phase 1	In-house
MT-8554	Nervous system etc.	Europe	Phase 1	In-house
MT-5199	Nervous system	Japan	Phase 1	US:Neurocrine Biosciences

2. Additional Indications & Administration

Product name (Generic name)	Category (Indications)	Region	Stage	Origin	Notes
Remicade (infliximab)	Anti-human TNF α monoclonal antibody (Psoriasis: increased dose)	Japan	sNDA filed (Jul., 2015)	US:Janssen Biotech	
	(Pediatric Crohn's disease)		Phase 3		
	(Pediatric ulcerative colitis)		Phase 3		
Imusera (fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Global clinical trial	Phase 3	In-house	Co-developed with Novartis Pharma in Japan, licensed to Novartis overseas
Canaglu (canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Global clinical trial	Phase 3	In-house	Sponsor: Janssen Research & Development, LLC

3. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee (Notes)
TA-7284 (canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus / fixed dose combination with metformin, XR)	US	NDA filed (Nov., 2015)	US: Janssen Pharmaceuticals, Inc
	(Diabetic nephropathy)	Global clinical trial	Phase 3	
	(Type 1 Diabetes Mellitus)	US, Canada	Phase 2	
	(Obesity / co-administration with phentermine)	US	Phase 2	
FTY720 (fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Global clinical trial	Phase 3	Switzerland: Novartis (Co-developed with Novartis Pharma in Japan)
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism in hemodialysis patients)	Japan	Phase 3	Japan: Kyowa Hakko Kirin
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	US: Minerva Neurosciences
MCC-847 (masilukast)	Leukotriene D4 receptor antagonist (Asthma)	Korea	Phase 2	Korea: SAMA Pharma
Wf-516	Multiple mechanisms on several receptors* (Depression)	Europe	Phase 2	US: Minerva Neurosciences
Y-803	Bromodomain inhibitor (Cancer)	Europe, Canada	Phase 2	US: Merck
sTU-199 (tenatoprazole)	Alimentary tract and metabolism	Europe	Phase 1	France: Negma/Sidem

*SSRI, 5-HT1A, dopamine transporter, and alpha-1A and B

4. Changes Since Previous Announcement on February 3, 2016

(1) New drugs

Development code (Generic name)	Category (Indications)	Region	As of Feb., 3, 2016	As of May 11, 2016	Origin
TAU-284 (bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis, Pediatric atopic dermatitis)	China	None	Filed (Mar., 2016)	Japan: Ube Industries
MT-5199	Nervous system	Japan	None	Phase 1	US:Neurocrine Biosciences

(2) Additional Indications & Administration

Product name (Generic name)	Category (Indications)	Region	As of Feb., 3, 2016	As of May 11, 2016	Notes
Tribik (adsorbed diphtheria- purified pertussis- tetanus combined vaccine)	Vaccine (Prophylaxis of pertussis, diphtheria, and tetanus; Stage 2 vaccination)	Japan	sNDA filed (Apr., 2015)	Approved (Feb., 2016)	Co-developed by MTPC and the Research Foundation for Microbial Diseases of Osaka University (MA holder)
Telavic (telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [combination with Feron])	Japan	Phase 3	Deleted	Cancellation of co- development agreement with Toray

5. Additional Information for State of New Product Development (As of May 11, 2016)

(1) New Drugs

Development code (Generic name)	Information
TA-650 (infliximab)	TA-650 is an anti-human TNF α monoclonal antibody. In Japan, it was launched under the brand name of Remicade in 2002.
TA-7284 (canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. It was launched in Japan for the treatment of type2 diabetes mellitus in September 2014, under the brand name of CANAGLU.
MP-513 (teneligliptin)	MP-513 selectively inhibits DPP-4, thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. It was launched in Japan for the treatment of type2 diabetes mellitus in September 2012, under the brand name of TENELIA.
MCI-186 (edaravone)	MCI-186 is a free radical scavenger. In Japan, it was launched under the brand name of Radicut® for the treatment of the acute stage of cerebral infarction in 2001, followed by inhibition on progression of functional disorder in patients with Amyotrophic Lateral Sclerosis (ALS) in Japan in June, 2015 and in Korea in December, 2015.
MT-2412 (teneligliptin, canagliflozin)	MT-2412 is a fixed-dose combination of Teneligliptin(DPP-4 inhibitor) and Canagliflozin(SGLT2 inhibitor).
MP-214 (cariprazine)	MP-214 is a dopamine D3/D2 receptor partial agonist, licensed from Gedeon Richter (Hungary). Efficacy on negative symptoms and cognitive functions in addition to positive symptoms for schizophrenia is expected.
MT-4666 (encenicline)	MT-4666, licensed from FORUM Pharmaceuticals(US), is an α 7nACh receptor agonist, which ameliorates cognitive dysfunction by activation of both the cholinergic system and the glutamatergic system.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist, which shows renoprotective effect on diabetic nephropathy.
MT-1303 (amiselimod)	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist, which keeps lymphocytes sequestered in the lymph nodes and prevents them from contributing to autoimmune reactions. It's a successor of Imusera/Gilenya.
MT-2301	MT-2301 is a Haemophilus influenza type b (Hib) vaccine, licensed from Nuron Biotech(US).
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of H5N1 influenza.
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of seasonal influenza.
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of H7N9 influenza.

(2) Additional Indications & Administration

Product name(Generic name)	Information
Remicade (infliximab)	Remicade is an anti-human TNF α monoclonal antibody. In Japan, it was launched as a treatment for Crohn's disease in 2002, followed by rheumatoid arthritis, intractable uveoretinitis caused by Behcet's disease, psoriasis, ankylosing spondylitis, ulcerative colitis, and entero-, neuro-, vasculo-Behcet's disease.
Imusera (fingolimod)	Imusera is a sphingosine-1-phosphate receptor functional antagonist, which keeps lymphocytes sequestered in the lymph nodes and prevents them from attacking the myelin of the nerve cells in multiple sclerosis. It was launched as a treatment for multiple sclerosis in 2011 in Japan. Imusera had been jointly developed with Novartis Pharma for the domestic market. Global Phase 3 study for chronic inflammatory demyelinating polyradiculoneuropathy is underway. It has been jointly developed with Novartis Pharma for the domestic market.
CANAGLU (canagliflozin)	As a selective SGLT2 inhibitor, CANAGLU decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. It was launched in Japan for the treatment of type2 diabetes mellitus in September, 2014. It was launched for the treatment of type2 diabetes mellitus under the brand name of INVOKANA by Janssen Pharmaceuticals, Inc. in the US and its affiliate in Europe.

(3) Licensing-out

Development code (Generic name)	Information
TA-7284 (canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. It was launched for the treatment of type2 diabetes mellitus under the brand name of INVOKANA by Janssen Pharmaceuticals, Inc. in the US and its affiliate in Europe. The fixed dose combination with metformin (IR) was approved in Europe (April, 2014) and the US (August, 2014).
FTY720 (fingolimod)	Sphingosine-1-phosphate receptor functional antagonist. It was launched as a treatment for multiple sclerosis under the brandname of Imusera by Mitsubishi Tanabe Pharma in Japan. It is also marketed under the brand name of Gilenya by Novartis.
Y-39983	Y-39983 is a ROCK (Rho-kinase) inhibitor, which relaxes vascular smooth muscles.
MT-210	MT-210 is a 5-HT2A/ Sigma 2 receptor antagonist.
MCC-847 (masilukast)	MCC-847 is a Leukotriene D4 receptor antagonist.
MT-4580	MT-4580 is a Ca sensing receptor agonist.
Wf-516	Wf-516 acts through multiple mechanisms on several receptors* associated with the control of mood. *SSRI, 5-HT1A, dopamine transporter, and alpha-1A and B
Y-803	Y-803 is a Bromodomain inhibitor.

7 Others

1 Subsidiaries and Affiliated Companies

(1) Number of Subsidiaries and Affiliated Companies

	End of FY2015	End of FY2014	Increase (Decrease)	Notes
Consolidated subsidiaries	28	28	0	Increase: MT Pharma America, Inc., MT Pharma Singapore Pte. Ltd. Decrease: Tanabe U.S.A., Inc., MP-Logistics Corporation
Non-consolidated subsidiaries	-	1	(1)	Decrease: Tanabe Seiyaku (Malaysia) Sdn. Bhd.
Affiliated companies	1	1	-	
Total	29	30	(1)	

(2) Consolidated Subsidiaries

[As of March 31, 2016]

	Company Name	Paid-in Capital	% Voting Control [% Indirect Ownership]	Settling Day	Description of Business
1	Yoshitomiya-kuhin Corporation	JPY 385 million	100.0 [-]	End of Mar.	Provision of information about pharmaceuticals
2	Bipha Corporation	JPY 100 million	100.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
3	Mitsubishi Tanabe Pharma Factory Ltd.	JPY 1,130 million	100.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
4	Tanabe Seiyaku Yoshiki Factory Co., Ltd.	JPY 400 million	100.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
5	Tanabe Seiyaku Hanbai., Ltd.	JPY 499 million	100.0 [-]	End of Mar.	Sale of generic pharmaceuticals, etc.
6	Tanabe R&D Service Co., Ltd.	JPY 44 million	100.0 [-]	End of Mar.	Support of R&D regarding pharmaceuticals
7	Tanabe Total Service Co., Ltd.	JPY 90 million	100.0 [-]	End of Mar.	Real estate management and creation of promotion materials, etc.
8	Mitsubishi Tanabe Pharma Holdings America, Inc.	USD 167	100.0 [-]	End of Mar.	Management of group companies in US
9	Mitsubishi Tanabe Pharma Development America, Inc.	USD 200	100.0 [100.0]	End of Mar.	R&D of pharmaceuticals
10	MT Pharma America, Inc.	USD 100	100.0 [100.0]	End of Mar.	Sale of pharmaceuticals
11	MP Healthcare Venture Management, Inc.	USD 100	100.0 [100.0]	End of Mar.	Investments in bio-ventures
12	Tanabe Research Laboratories U.S.A., Inc.	USD 3,000,000	100.0 [100.0]	End of Mar.	R&D of pharmaceuticals
13	MTPC Holdings Canada Inc.	CAD 287 million	100.0 [-]	End of Mar.	Investments in Medicago Group
14	Medicago Inc.	CAD 328 million	60.0 [56.5]	End of Mar.	Manufacture and sale of vaccines
15	Medicago USA Inc.	USD 99	60.0 [60.0]	End of Mar.	Manufacture of vaccines
16	Medicago R&D Inc.	CAD 500	60.0 [60.0]	End of Mar.	R&D of vaccines
17	Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd.	USD 1,000,000	100.0 [-]	End of Dec.	R&D of pharmaceuticals
18	Tianjin Tanabe Seiyaku Co., Ltd.	USD 16,230,000	75.4 [-]	End of Dec.	Manufacture and sale of pharmaceuticals
19	Guangdong Tanabe Pharmaceutical Co., Ltd.	CNY 7,000,000	100.0 [-]	End of Dec.	Sale of pharmaceuticals
20	Taiwan Tanabe Seiyaku Co., Ltd.	TWD 90,000,000	65.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
21	Tai Tien Pharmaceuticals Co., Ltd.	TWD 20,000,000	65.0 [-]	End of Mar.	Sale of pharmaceuticals
22	P.T. Tanabe Indonesia	USD 2,500,000	99.6 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
23	MT Pharma Singapore Pte. Ltd.	SGD 300,000	100.0 [-]	End of Mar.	R&D of pharmaceuticals
24	Mitsubishi Tanabe Pharma Korea Co., Ltd.	KRW 2,100,000,000	100.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
25	Mitsubishi Tanabe Pharma Europe Ltd.	GBP 4,632,000	100.0 [-]	End of Mar.	R&D of pharmaceuticals
26	Mitsubishi Tanabe Pharma GmbH	EUR 25,000	100.0 [100.0]	End of Mar.	Sale of pharmaceuticals

Note: Aside from the companies mentioned above, there are two consolidated companies under the liquidations.

(3) Affiliated Companies Accounted for by the Equity Method

[As of March 31, 2016]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]	Settling Day	Description of Business
1	Synthelabo-Tanabe Chimie S.A.	EUR 1,600,000	50.0 [-]	End of Dec.	Manufacture and sale of pharmaceuticals

2 Status of Shareholders

(1) Number of Outstanding Shares

	End of March, 2016	End of March, 2015
Issued	561,417,916	561,417,916
The company's own shares at the end of the period	428,945	428,340
Number of shares outstanding at the end of the period	560,988,971	560,989,576
Average number of the company's own share in the period	428,670	427,456
Average number of shares outstanding in the period	560,989,246	560,990,460

(2) Status of Major Shareholders

Rank	Name of Shareholders	End of March, 2016		End of March, 2015		
		Number of Shares (Thousands)	Percentage of Total	Rank	Number of Shares (Thousands)	Percentage of Total
1	Mitsubishi Chemical Holdings Corporation	316,320	56.34%	1	316,320	56.34%
2	The Master Trust of Japan, Ltd.	25,438	4.53%	2	24,137	4.30%
3	Nippon Life Insurance Company	12,065	2.15%	3	12,065	2.15%
4	Japan Trustee Services Bank, Ltd.	11,199	1.99%	4	10,669	1.90%
5	The Bank of Tokyo-Mitsubishi UFJ, Ltd.	7,254	1.29%	5	7,254	1.29%
6	Japan Trustee Services Bank, Ltd. (Trust Account 9)	6,176	1.10%	12	3,449	0.61%
7	STATE STREET BANK WEST CLIENT-TREATY 505234	5,602	1.00%	10	3,635	0.65%
8	STATE STREET BANK AND TRUST COMPANY 505225	4,552	0.81%	6	5,488	0.98%
9	Employee Stock Ownship Plan	4,002	0.71%	7	4,505	0.80%
10	Nipro Corporation	3,821	0.68%	9	3,821	0.68%

(3) Ownership and Distribution of Shares

	End of March, 2016			End of March, 2015		
	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total
Financial institutions	79	101,203	18.03%	75	98,321	17.52%
Foreign corporations and others	515	97,796	17.42%	465	100,650	17.93%
Individuals and others	16,396	25,295	4.51%	13,972	24,578	4.38%
Other corporations	265	332,740	59.28%	251	334,680	59.62%
Securities firms	36	4,276	0.76%	34	3,083	0.55%
Total	17,291	561,311	100.00%	14,797	561,315	100.00%
Less than trading unit	-	106	-	-	102	-

* The trading unit of the Company's stock is 100 shares.

* Individuals and Others include treasury stocks (428 thousands shares at the end of March, 2016 and 428 thousands shares at the end of March, 2015)

(4) Trend of Dividend and Stock Price

	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016 Estimate
Dividends per share (yen)	35	40	40	42	46	48
Dividend payout ratio(%)	50.3	53.6	49.4	59.6	45.7	47.2
Stock price at the end of FY	1,161	1,445	1,443	2,062	1,957	-
Market capitalization (billion yen)	6,518	8,112	8,101	11,576	10,987	-

Dividend payout ratios until FY2015 are based on Japan GAAP (after amortization of goodwill). Dividend payout ratio estimate of FY2016 is based on IFRS (non-amortization of goodwill).

Reference

Major Ethical Drugs

Remicade (Infliximab)	Launch: May 2002	Category	Anti-TNF α monoclonal antibody
<p>Remicade is an anti-TNFα antibody, which targets TNFα, an important inflammatory cytokine. It is very fast-acting and its efficacy is sustained for eight weeks with a single administration. It has indications for the treatment of rheumatoid arthritis, Crohn's disease, Behcet's disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis. In addition, in July 2009 and August 2011, changes in usage/dosage were approved for rheumatoid arthritis, and Crohn's disease, respectively.</p> <p>Entero-Behcet's disease, neuro-Behcet's disease, and vasculo-Behcet's disease in cases where existing treatment is inadequate were approved in August, 2015. And Kawasaki disease was approved in December 2015. Partial change in dosage and usage (increased dose) for psoriasis was filed in July 2015.</p> <p>Origin: Janssen Biotech</p>			
Talion (Bepotastine)	Launch: Oct. 2000	Category	Agent for treatment of allergic disorders
<p>Talion has rapid onset of anti-histamine(H1) effects and has been demonstrated to be effective for allergic rhinitis, urticaria, and pruritus accompanying dermatitis. It has minimal incidence of sedation. An additional formulation, orally disintegrating tablets was launched in July 2007. Pediatric indications (from seven to fifteen years old) was approved in May 2015.</p> <p>Origin: Ube Industries</p>			
Ceredist (Taltirelin)	Launch: Sep. 2000	Category	Agent for treatment of spinocerebellar degeneration
<p>Thyrotropin releasing hormone (TRH) was known to be effective against ataxia caused by spinocerebellar degeneration, but it was previously administered only through injection. Ceredist is the world's first oral TRH derivative drug by in-house development. An additional formulation, orally disintegrating tablets, was launched in October 2009.</p>			
Tenelia (Teneligliptin)	Launch: Sep. 2012	Category	Selective DPP-IV inhibitor
<p>Tenelia, which Mitsubishi Tanabe has created and developed, is the first DPP-4 inhibitor originating in Japan. It inhibits the function of dipeptidyl peptidase-4 (DPP-4), which selectively breaks down glucagon-like peptide-1(GLP-1), a hormone secreted from the gastrointestinal tract in response to food intake. In this way, Tenelia promotes insulin secretion and suppresses glucagon secretion, thereby demonstrating blood glucose lowering action.</p>			
Maintate (Bisoprolol)	Launch: Nov. 1990	Category	Selective β 1 antagonist (Treatment of hypertension, angina pectoris, and arrhythmias, chronic heart failure)
<p>Maintate is a representative β-blocker used in more than 100 countries around the world. It exhibits high selectivity for β 1 receptor and excellent pharmacokinetics profiles. It has high efficacy and safety, and evidence-based cardioprotective action. In addition to the indication of chronic heart failure which was approved in May 2011, the indication of atrial fibrillation has been newly approved in June 2013 . Maintate is the only β-blocker with both indications of chronic heart failure and atrial fibrillation in Japan.</p> <p>Origin: Merck Serono (Germany)</p>			
Simponi (Golimumab)	Launch: Sep. 2011	Category	Anti-TNF α monoclonal antibody
<p>Simponi is a human anti-TNFα monoclonal antibody for the treatment of rheumatoid arthritis (including prevention of articular structural damage). It shows a long acting efficacy by subcutaneous injection once every four weeks. Additional indication of ulcerative colitis was filed in April 2016 by Janssen Pharmaceutical.</p> <p>Origin: Janssen Biotech</p>			
Lexapro (Escitalopram)	Launch: Aug. 2011	Category	Selective serotonin reuptake inhibitor (SSRI)
<p>Lexapro, a highly selective serotonin reuptake inhibitor (SSRI), has been globally approved in 98 countries and regions. It shows good efficacy and tolerability in patients with depressive disorder. Moreover, due to simple dosage and administration, it is expected to improve adherence of the treatment. Social anxiety disorder (SAD) was approved in November 2015.</p> <p>Origin: H. Lundbeck A/S (Denmark), Manufacturer and distributor: Mochida Pharmaceutical Co., Ltd</p>			
Kremezin	Launch: Apr. 2011	Category	Agent for treatment of Chronic renal failure
<p>Kremezin is an oral absorptive charcoal consisting of porous spherical activated carbon of high purity. It absorbs and excretes uremic toxins out of the body. Keremezin was introduced to the Japanese market in December 1991 as the first pharmaceuticals drug in the world for proactive treatment of chronic renal failure (progressive). In April 2011, the marketing rights were transferred from Daiichi Sankyo to MTPC.</p> <p>Origin, Manufacturer and distributor: Kureha</p>			

Urso (Ursodeoxycholic Acid)	Launch: July 1962	Category	Agent for improving hepatic, biliary and digestive functions
Ursodeoxycholic acid (UDCA), principal ingredient of Urso, had been extracted from blackbear's gallbladder in the past and has been used in the treatment of various digestive diseases. It is one of the bile acids existing in the human body. Urso has effects of hepatic protection and indications of improvement of liver function in chronic liver disease and hepatitis C, and dissolution of gallstones.			
Depas (Etizolam)	Launch: Mar. 1984	Category	Antianxiety agent
Depas is the most widely used anxiolytic agent in Japan. Due to its broad pharmacological properties, Depas shows reasonable effectiveness for psychosomatic disease, neurosis, low back pain, neck pain and muscle-contraction headache, depression and sleep disorder.			
Radicut (Edaravone)	Launch: Jun. 2001	Category	Free radical scavenger (Cerebral neuroprotectant)
Radicut is the world's first brain protecting agent (free radical scavenger) shown to improve neurological symptoms, interference with activities of daily living, and disability (at hospital discharge) in patients at acute stage of cerebral infarction. Specific indications include the treatment of various types of infarction (cerebral lacunar, atherothrombotic and cardiogenic infarction) It is initiated administration within 24 hours after onset, and is not administered for more than 14 days. An additional formulation, Radicut bag for I.V. Infusion, was launched in May 2010. It was designated as an orphan drug of amyotrophic lateral sclerosis (ALS) and approved for ALS in June, 2015.			
Anplag (Sarpogrelate)	Launch: Oct. 1993	Category	5-HT2 blocker (Anti-platelet agent)
Anplag, an oral anti-platelet, is used to patients with arteriosclerosis obliterans (ASO) to improve ischemic symptoms like as ulcer, pain and coldness of limbs associated with chronic arterial occlusion. Anplag especially improves the bloodstream of collateral circulation and inhibits platelet aggregation, vascular contraction and growth of vascular smooth muscle cell by antagonistic action to serotonin receptor in platelets and vessels.			
TETRABIK (Absorbed Diphtheria-purified Pertussis-tetanus inactivated polio)	Launch: Oct. 2012	Category	Prevention of diphtheria, pertussis, tetanus and polio
TETRABIK is a combined vaccine that prevents acute poliomyelitis (polio), pertussis, diphtheria and tetanus. It is used at 1st term (initial 3 times) and 1st term (additional 1 time), in total 4 times, of the regular vaccination. By using TETRABIK, It is expected to avoid the very rare occurrence of paralytic symptoms similar to those in natural polio due to live-attenuated oral polio vaccine. Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)			
Mearubik (Live Attenuated Measles and Rubella Vaccine)	Launch: Dec. 2005	Category	Prevention of measles and rubella
Mearubik is the combination vaccine for measles and rubella, and children are able to receive both measles and rubella shot at a time with Mearubik, which is used at the 1st term and the 2nd term of its regular vaccination. By both reducing the number of injections and relieving physical pain on people to be vaccinated, It is expected to contribute enhancement of immunization rate for measles and rubella in Japan. Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)			

News Releases

The major news releases after October, 2015 are as follows.

Please refer to the Company's website for the details. (<http://www.mt-pharma.co.jp/e/release/index.php>)

Date	Contents
October 2, 2015	Mitsubishi Tanabe Pharma and Regeneron Conclude Collaboration Agreement for Fasinumab, NGF Antibody
October 30, 2015	Medicago Engaged by the Canadian Government Produce Ebola Monoclonal Antibodies
October 30, 2015	Notice Regarding Implementation of Early Retirement Program
November 20, 2015	Announcement of an approval for an additional indication for the Anti-depressant, Lexapro Tablets 10 mg in Japan
November 30, 2015	Formulation of the Medium-Term Management Plan 16-20: Open Up the Future
December 15, 2015	Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
December 21, 2015	RADICUT inj. 30mg and RADICUT Infusion inj. 30mg An import and Marketing Permission for ALS in South Korea
December 21, 2015	Remicade for I.V. Infusion 100 Approval of Additional Indication for Kawasaki Disease World First Biologic Treatment
February 3, 2016	Notice Regarding Results of Early Retirement Program
February 23, 2016	MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolbenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer
March 10, 2016	Notice regarding change of current commercialization scheme to new strategic co-promotion partnership in Japan for RA treatment agent Simponi subcutaneous injection 50 mg syringe (generic name: golimumab)
March 22, 2016	Valixa Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based Application
March 29, 2016	Valixa Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based Application
April 4, 2016	MT Pharma Singapore Pte. Ltd. Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in Singapore
April 27, 2016	Change of Representative Director, Director and Corporate Auditor



Mitsubishi Tanabe Pharma

Financial Results for the Fiscal Year Ended March 31, 2016

<Supplement>